About this trial
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE
Patient Profile
For patients with Cancer Associated Venous Thromboembolism
Where’s this trial being run?
Beaumont Hospital, Bon Secours Cork, Cork University Hospital, University Hospital Limerick, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | ANTHOS ANT 007 – Aster |
|---|---|
| Number: | 24-11 |
| Full Title: | A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE |
| Principal Investigator: | Dr Barry Kevane |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Anthos Therapeutics, Inc. |
| Recruitment Started: |
Global: Ireland: |
| Global Recruitment Target: | 1655 |
|---|---|
| Ireland Recruitment Target: |